Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Autores
Itkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; Haab, Gabriela Acosta; Bardach, Ariel Esteban
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
Fil: Itkin, Boris. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Garcia, Agustin. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Straminsky, Samanta. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Adelchanow, Eduardo Daniel. Hospital Nacional Profesor Alejandro Posadas.; Argentina
Fil: Pereyra, Matias. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Haab, Gabriela Acosta. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Materia
INMUNOHISTOCHEMISTRY
MALIGNANT TUMORS
HISTOLOGY
UTERINE CANCER
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/184501
Acceder
id CONICETDig_7241f4622ac5c338c2038710b865d44c
oai_identifier_str oai:ri.conicet.gov.ar:11336/184501
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysisItkin, BorisGarcia, AgustinStraminsky, SamantaAdelchanow, Eduardo DanielPereyra, MatiasHaab, Gabriela AcostaBardach, Ariel EstebanINMUNOHISTOCHEMISTRYMALIGNANT TUMORSHISTOLOGYUTERINE CANCERhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.Fil: Itkin, Boris. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Garcia, Agustin. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;Fil: Straminsky, Samanta. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Adelchanow, Eduardo Daniel. Hospital Nacional Profesor Alejandro Posadas.; ArgentinaFil: Pereyra, Matias. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Haab, Gabriela Acosta. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaPublic Library of Science2021-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/184501Itkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; et al.; Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis; Public Library of Science; Plos One; 16; 9; 9-2021; 1-241932-6203CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257976info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0257976info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:01:55Zoai:ri.conicet.gov.ar:11336/184501instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:01:56.23CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
title Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
spellingShingle Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
Itkin, Boris
INMUNOHISTOCHEMISTRY
MALIGNANT TUMORS
HISTOLOGY
UTERINE CANCER
title_short Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
title_full Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
title_fullStr Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
title_full_unstemmed Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
title_sort Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
dc.creator.none.fl_str_mv Itkin, Boris
Garcia, Agustin
Straminsky, Samanta
Adelchanow, Eduardo Daniel
Pereyra, Matias
Haab, Gabriela Acosta
Bardach, Ariel Esteban
author Itkin, Boris
author_facet Itkin, Boris
Garcia, Agustin
Straminsky, Samanta
Adelchanow, Eduardo Daniel
Pereyra, Matias
Haab, Gabriela Acosta
Bardach, Ariel Esteban
author_role author
author2 Garcia, Agustin
Straminsky, Samanta
Adelchanow, Eduardo Daniel
Pereyra, Matias
Haab, Gabriela Acosta
Bardach, Ariel Esteban
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv INMUNOHISTOCHEMISTRY
MALIGNANT TUMORS
HISTOLOGY
UTERINE CANCER
topic INMUNOHISTOCHEMISTRY
MALIGNANT TUMORS
HISTOLOGY
UTERINE CANCER
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
Fil: Itkin, Boris. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Garcia, Agustin. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Straminsky, Samanta. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Adelchanow, Eduardo Daniel. Hospital Nacional Profesor Alejandro Posadas.; Argentina
Fil: Pereyra, Matias. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Haab, Gabriela Acosta. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
description The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
publishDate 2021
dc.date.none.fl_str_mv 2021-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/184501
Itkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; et al.; Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis; Public Library of Science; Plos One; 16; 9; 9-2021; 1-24
1932-6203
CONICET Digital
CONICET
url http://hdl.handle.net/11336/184501
identifier_str_mv Itkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; et al.; Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis; Public Library of Science; Plos One; 16; 9; 9-2021; 1-24
1932-6203
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257976
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0257976
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781215398428672
score 12.982451

Publicaciones similares